Quethera Ltd


Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. The initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

On 10 August 2018, Japanese Astellas Pharma bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.

Midven’s UK Innovation & Science Seed Fund (UKI2S) was the founding investor with follow-on, co-investment from Cambridge Enterprise.

Under the terms of the purchase agreement, Astellas may pay up to $109 million in aggregate consideration (upfront and contingent payments) to Quethera shareholders to acquire Quethera.  The full announcement may be found here.

Associated Team Members

Relevant News

Former Quethera leadership wins BVCA Management Team Award

14th June 2019 / UKI2S, a leading early-stage venture capital fund facilitating the growth of UK life science companies, congratulates the former management team of Quethera led by CEO…

Read More

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma TOKYO, CAMBRIDGE (UK), August 10, 2018 – Astellas Pharma Inc. (TSE: 4503, President…

Read More

Neuroprotective Therapy Company Quethera Reveals Gene Therapy Results at ARVO

Quethera, a biopharmaceutical company developing therapies for ocular disorders, today presented strong efficacy data at the 2017…

Read More

Quethera Announces Seed Financing To Develop Gene Therapy Aimed At Preventing Blindness In Glaucoma Patients

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven’s UK Innovation & Science Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

Read More
Show More